The controversies of statin therapy: Weighing the evidence

Journal of the American College of Cardiology

Volumn 60, Issue 10, 2012, Pages 875-881

  Jukema, J Wouter ^a,b,c   Cannon, Christopher P ^d   De Craen, Anton J M ^a,e   Westendorp, Rudi G J ^a,e,f   Trompet, Stella ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Durrer Center for Cardiogenetic Research   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Netherlands Consortium for Healthy Ageing   (Netherlands)

^f Leyden Academy for Vitality and Ageing   (Netherlands)

Author keywords

adverse effects; cancer; cognitive decline; diabetes mellitus; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AMNESIA; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC);

CARDIOVASCULAR DISEASES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; DRUG LABELING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MENDELIAN RANDOMIZATION ANALYSIS; META-ANALYSIS AS TOPIC; MILD COGNITIVE IMPAIRMENT; NEOPLASMS; PSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865497225     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.007     Document Type: Review

References (70)

1. P.G. McGovern, J.S. Pankow, E. Shahar Recent trends in acute coronary heart diseasemortality, morbidity, medical care, and risk factors The Minnesota Heart Survey Investigators N Engl J Med 334 1996 884 890
2. M. Alberton, P. Wu, E. Druyts, M. Briel, E.J. Mills Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis Q J Med 105 2012 145 157
3. FDA.orgThe Center For Health and Wellness http://www.fda.org/drugs/ drugssafety/ucm293101.htm Accessed April 25, 2012
4. C.H. Rojas-Fernandez, J.C. Cameron Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations Ann Pharmacother 46 2012 549 557
5. L.R. Wagstaff, M.W. Mitton, B.M. Arvik, P.M. Doraiswamy Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy 23 2003 871 880
6. J.P. Vandenbroucke Observational research, randomised trials, and two views of medical science PLoS Med 5 2008 e67
7. B.A. Morris The importance of case reports Can Med Assoc J 141 1989 875 876
8. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
9. I. Hajjar, J. Schumpert, V. Hirth, D. Wieland, G.P. Eleazer The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment J Gerontol 57A 2002 M414 M418
10. K. Rockwood, S. Kirkland, D.B. Hogan Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch Neurol 59 2002 223 227
11. K. Yaffe, E. Barrett-Connor, F. Lin, D. Grady Serum lipoprotein levels, statin use, and cognitive function in older women Arch Neurol 59 2002 378 384
12. J.M. Starr, B. McGurn, M. Whiteman, A. Pattie, L.J. Whalley, I.J. Deary Life long changes in cognitive ability are associated with prescribed medications in old age Int J Geriatr Psychiatry 19 2004 327 332
13. J.V. Agostini, M.E. Tinetti, L. Han, G. McAvay, J.M. Foody, J. Concato Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults J Am Geriatr Soc 55 2007 420 425
14. D.A. Redelmeier, D. Thiruchelvam, N. Daneman Delirium after elective surgery among elderly patients taking statins Can Med Assoc J 179 2008 645 652
15. S.P. Glasser, V. Wadley, S. Judd The association of statin use and statin type and cognitive performance: analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study Clin Cardiol 33 2010 280 288
16. J. Benito-Leon, E.D. Louis, S. Vega, F. Bermejo-Pareja Statins and cognitive functioning in the elderly: a population-based study J Alzheimers Dis 21 2010 95 102
17. G. Danaei, M. Tavakkoli, M.A. Hernan Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins Am J Epidemiol 175 2012 250 262
18. J.P. Vandenbroucke The HRT controversy: observational studies and RCTs fall in line Lancet 373 2009 1233 1235
19. D.J. Magliano, S.L. Rogers, M.J. Abramson, A.M. Tonkin Hormone therapy and cardiovascular disease: a systematic review and meta-analysis BJOG 113 2006 5 14
20. L.D. Cowan, D.L. O'Connell, M.H. Criqui, E. Barrett-Connor, T.L. Bush, R.B. Wallace Cancer mortality and lipid and lipoprotein levels Lipid Research Clinics Program mortality follow-up study Am J Epidemiol 131 1990 468 482
21. C. Iribarren, D.M. Reed, R. Chen, K. Yano, J.H. Dwyer Low serum cholesterol and mortality Which is the cause and which is the effect? Circulation 92 1995 2396 2403
22. A. Keys, C. Aravanis, H. Blackburn Serum cholesterol and cancer mortality in the Seven Countries Study Am J Epidemiol 121 1985 870 883
23. P. Knekt, A. Reunanen, A. Aromaa, M. Heliovaara, T. Hakulinen, M. Hakama Serum cholesterol and risk of cancer in a cohort of 39,000 men and women J Clin Epidemiol 41 1988 519 530
24. A.J. Schuit, C.E. Van Dijk, J.M. Dekker, E.G. Schouten, F.J. Kok Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants Am J Epidemiol 137 1993 966 976
25. A.W. Weverling-Rijnsburger, G.J. Blauw, A.M. Lagaay, D.L. Knook, A.E. Meinders, R.G. Westendorp Total cholesterol and risk of mortality in the oldest old Lancet 350 1997 1119 1123
26. S.B. Kritchevsky, D. Kritchevsky Serum cholesterol and cancer risk: an epidemiologic perspective Annu Rev Nutr 12 1992 391 416
27. S. Trompet, J.W. Jukema, M.B. Katan Apolipoprotein E genotype, plasma cholesterol, and cancer: a Mendelian randomization study Am J Epidemiol 170 2009 1415 1421
28. R. Sukhija, S. Prayaga, M. Marashdeh Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients J Invest Med 57 2009 495 499
29. A.L. Culver, I.S. Ockene, R. Balasubramanian Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative Arch Intern Med 172 2012 144 152
30. J. Concato, N. Shah, R.I. Horwitz Randomized, controlled trials, observational studies, and the hierarchy of research designs N Engl J Med 342 2000 1887 1892
31. J. Concato, R.I. Horwitz Beyond randomised versus observational studies Lancet 363 2004 1660 1661
32. O.S. Miettinen The need for randomization in the study of intended effects Stat Med 2 1983 267 271
33. J.P. Vandenbroucke When are observational studies as credible as randomised trials? Lancet 363 2004 1728 1731
34. R.A. Whitmer, S. Sidney, J. Selby, S.C. Johnston, K. Yaffe Midlife cardiovascular risk factors and risk of dementia in late life Neurology 64 2005 277 281
35. M. Kivipelto, E.L. Helkala, M.P. Laakso Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study BMJ 322 2001 1447 1451
36. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
37. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
38. F.B. Hu, J.E. Manson, M.J. Stampfer Diet, lifestyle, and the risk of type 2 diabetes mellitus in women N Engl J Med 345 2001 790 797
39. J.C. Seidell Obesity, insulin resistance and diabetesa worldwide epidemic Br J Nutr 83 Suppl 1 2000 5 8
40. J. Shepherd, G.J. Blauw, M.B. Murphy Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
41. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
42. S. Trompet, V.P. van, A.J. de Craen Pravastatin and cognitive function in the elderly Results of the PROSPER study J Neurol 257 2010 85 90
43. R. Clarke, P. Xu, D. Bennett Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study PLoS Genet 2 2006 e107
44. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Gaithersburg, Maryland, December 15, 2009. CRESTOR (Rosuvastatin calcium), NDA 21-366, JUPITER, Mary Dunne Roberts, MD, Division of Metabolism and Endocrinology Products http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm194918.pdf Accessed May 30, 2012
45. R.W. Harrison, C.H. Ashton Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers Br J Clin Pharmacol 37 1994 231 236
46. J.B. Kostis, R.C. Rosen, A.C. Wilson Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia J Clin Pharmacol 34 1994 989 996
47. N. Cutler, J. Sramek, A. Veroff, G. Block, L. Stauffer, C. Lines Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia Br J Clin Pharmacol 39 1995 333 336
48. F. Gengo, D. Cwudzinski, P. Kinkel, G. Block, L. Stauffer, C. Lines Effects of treatment with lovastatin and pravastatin on daytime cognitive performance Clin Cardiol 18 1995 209 214
49. N.C. Santanello, B.L. Barber, W.B. Applegate Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) pilot study J Am Geriatr Soc 45 1997 8 14
50. M.F. Muldoon, C.M. Ryan, S.M. Sereika, J.D. Flory, S.B. Manuck Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults Am J Med 117 2004 823 829
51. M.F. Muldoon, S.D. Barger, C.M. Ryan Effects of lovastatin on cognitive function and psychological well-being Am J Med 108 2000 538 546
52. M.G. Gibellato, J.L. Moore, K. Selby, E.A. Bower Effects of lovastatin and pravastatin on cognitive function in military aircrew Aviat Space Environ Med 72 2001 805 812
53. B.A. Golomb, J.E. Dimsdale, H.L. White, M.H. Criqui Results of the UCSD statin study Do low dose statins affect cognition? Circulation 114 2006 II289
54. G.P. Parale, N.N. Baheti, P.M. Kulkarni, N.V. Panchal Effects of atorvastatin on higher functions Eur J Clin Pharmacol 62 2006 259 265
55. M.J. Summers, K.R. Oliver, J.S. Coombes, R.G. Fassett Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial Pharmacotherapy 27 2007 183 190
56. I. Berk-Planken, I. de Konig, R. Stolk, H. Jansen, N. Hoogerbrugge Atorvastatin, diabetic dyslipidemia, and cognitive functioning Diabetes Care 25 2002 1250 1251
57. A.A. Alsheikh-Ali, T.A. Trikalinos, D.M. Kent, R.H. Karas Statins, low-density lipoprotein cholesterol, and risk of cancer J Am Coll Cardiol 52 2008 1148 1149
58. D. Hunt, P. Young, J. Simes Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial Ann Intern Med 134 2001 931 940
59. S. Bonovas, K. Filioussi, C.S. Flordellis, N.M. Sitaras Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients J Clin Oncol 25 2007 3462 3468
60. S. Bonovas, N.M. Sitaras Does pravastatin promote cancer in elderly patients? A meta-analysis Can Med Assoc J 176 2007 649 654
61. C. Baigent, L. Blackwell, J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
62. J.J. Brugts, T. Yetgin, S.E. Hoeks The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials BMJ 338 2009 b2376
63. K.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger, C.M. White Statins and cancer risk: a meta-analysis JAMA 295 2006 74 80
64. J.R. Emberson, P.M. Kearney, L. Blackwell Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy PLoS One 7 2012 e29849
65. S. Bonovas, G. Nikolopoulos, N.M. Sitaras Efficacy and safety of more intensive lowering of LDL cholesterol Lancet 377 2011 715 716
66. N. Sattar, D. Preiss, H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
67. P.M. Ridker, E. Danielson, F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
68. D.J. Freeman, J. Norrie, N. Sattar Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362
69. D. Preiss, S.R. Seshasai, P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
70. J.E. Mallinson, D. Constantin-Teodosiu, J. Sidaway, F.R. Westwood, P.L. Greenhaff Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J Physiol 587 2009 219 230